11 hrs ago
Investor's Business Daily
Top Mutual Fund Manager Seeks Mispriced Growth
He waits for them to focus on short-term factors in a good security's price in the stock market today . When they flee from the stock, driving down its price, Hamzaogullari pounces.
17 hrs ago
Study Shows Novo Nordisk A/S's New Diabetes Drug Tresiba Effective And Safe For Children
New data show long-term efficacy and safety of Tresiba in children and adolescents with type 1 diabetes Vienna, Austria, 16 September - Today, at the 50 Annual Meeting of the European Association for the Study of Diabetes , Novo Nordisk announced new data from the BEGIN versus insulin detemir, both in combination with bolus insulin aspart in a 52-week trial in children and adolescents with type 1 diabetes. This trial is the first to look into the long-term safety of Tresiba "When treating children and adolescents with type 1 diabetes, it is critical that the right balance between glycaemic control and side effect management is maintained to ensure the best possible long-term outcomes.
21 hrs ago
South China Morning Post
Novo's weight-loss shot wins backing of U.S. advisers
Students wait in line to get a meal at Wellspring Academy, which is a special school that helps teens and college level students lose weight along with academic courses. Photo: AFP A weight-loss drug from Novo Nordisk helped people get thinner, U.S. regulators said, as the Danish drugmaker became the latest to push a pharmaceutical remedy for America's obesity woes.
Mon Sep 15, 2014
Congress, MAGIC Call for Early Detection and Awareness of Children's Growth Patterns
The MAGIC Foundation , a nonprofit organization that provides support services for the families of children afflicted with a wide variety of chronic and/or critical disorders, syndromes, and diseases that affect a child's growth, is proud to support, in partnership with Novo Nordisk, the first nationally recognized Growth Awareness Week. This is a significant milestone for children everywhere because it puts a national spotlight on the need for parents to better educate themselves on proper growth patterns.
Sun Sep 14, 2014
FDA panel backs Novo Nordisk injection
FEDERAL health experts say Novo Nordisk's diabetes drug Victoza should be approved for a new use in treating obesity. THE panel of Food and Drug Administration advisers voted 14-1 that the injectable drug's benefits outweigh its risks for patients who are obese or dangerously overweight.
Novo Nordisk and the diabetes epidemic
Sep 14, 2014 : Rising insulin sales have made Novo Nordisk one of the strongest growth stories in the pharma sector.
Fri Sep 12, 2014
Novo Gets Positive Vote From FDA For Anti-Obesity Treatment - Still A Long Road Ahead
Novo Nordisk received good news earlier this week in its quest to get an obesity indication for its drug Saxenda. The drug is a different dose form of liaglutide that would be injected once a day for patienmts seeking to treat obesity.
The Motley Fool
Surprising New Competitor: Should Arena Pharmaceuticals, Inc. and Orexigen Therapeutics, Inc. Be Afr
A heavier population has significantly increased concerns over obesity's impact on global health, resulting in a flurry of drug development activity and FDA approval of weight loss pills. ) novel anti-obesity pills are among three drugs that the FDA has approved for use alongside diet and exercise to promote weight loss.
UPDATE 3-U.S. FDA panel: Novo Nordisk's liraglutide safe, effective for obesity
Novo Nordisk's drug liraglutide is safe and effective enough to warrant approval for use in chronically obese patients with at least one weight-related health issue, an advisory panel to the U.S. Food and Drug Administration said on Thursday. The positive vote sent shares in the company, the Nordic region's most valuable by market capitalisation, to an all-time high of 275.60 Danish crowns on Friday, up more than 3 percent.
Thu Sep 11, 2014
Saxenda for the treatment of obesity receives positive 14-1 vote in...
Novo Nordisk today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the Food and Drug Administration has completed its meeting regarding the New Drug Application for Saxenda , the intended brand name for liraglutide 3 mg, a once-daily human GLP-1 analogue for the treatment of obesity. Based on the data contained in the NDA for Saxenda , the FDA asked the panel members to discuss whether Novo Nordisk has provided adequate evidence to establish the efficacy and safety profile of Saxenda for chronic weight management.
FDA Approves New Weight Loss Injection
Federal health experts say a diabetes drug from Novo Nordisk should be approved for a new use in treating obesity. The panel of Food and Drug Administration advisers voted 14-1 that the injectable drug's benefits outweigh it risks for patients who are obese or dangerously overweight.
FDA panel backs Novo Nordisk injection for obesity
Prosecutors are wrapping up their case against the owner of a Georgia peanut plant linked to a deadly salmonella outbreak, saying he knowingly approved shipments of tainted food "whatever the risk." The owner of a Georgia peanut plant where a deadly salmonella outbreak originated five years ago approved sales of tainted food "whatever the risk," including shipments known to have tested positive for the bacteria and... A 40-year-old driver has been accused of intentionally driving a pickup truck through the glass doors of the Stratosphere casino on the Las Vegas Strip.
Wed Sep 10, 2014
South China Morning Post
New obesity drug wins FDA approval, and this time it could take off
Students wait in line to get a meal at Wellspring Academy, which is a special school that helps teens and college level students lose weight along with academic courses. Photo: AFP The US Food and Drug Administration has endorsed the weight-loss capabilities of a new drug from Novo Nordisk, as the Danish drugmaker became the latest to push a pharmaceutical remedy for America's obesity woes.
Tue Sep 09, 2014
UPDATE 1-FDA staff: Novo Nordisk drug liraglutide effective for obesity
Novo Nordisk's drug liraglutide appears effective in treating obesity, though safety questions remain, according to a preliminary assessment by reviewers at the U.S. Food and Drug Administration. The report, posted on the agency's website on Tuesday, noted an imbalance in the number of breast malignancies in women who took the drug, but said the available data neither supports nor denies the potential role of the drug in cancer promotion or progression.
Mon Sep 08, 2014
More Obesity Drugs Seek to Enter Still Struggling Market
Drugmakers aren't giving up on a pharmaceutical remedy for America's obesity woes even as sales for much-anticipated weight-loss pills have fallen short of estimates. The Food and Drug Administration is scheduled to decide by Sept.
Thu Sep 04, 2014
Piramal, Exelixis And Novo Nordisk Research Woes Spell Doom For Drug Discovery Scientists
I was the president of Pfizer Global Research and Development in 2007 where I managed more than 13,000 scientists and professionals in the United States, Europe, and Asia. I've received numerous awards including an Honorary Doctor of Science degree from the University of New Hampshire.
Merrion Pharma get milestone payment
Dublin's Merrion Pharmaceuticals today said that it has received a milestone payment from its partner, Novo Nordisk, after a Phase 1 clinical trial with an oral diabetes-fighting drug. This class of compound stimulates the release of insulin in appropriate diabetic subjects, and is currently administered by injection.
Wed Sep 03, 2014
Novo Nordisk cuts 63 jobs at Seattle research site
Danish pharmaceutical company Novo Nordisk is eliminating 63 Seattle jobs and closing its inflammation research center, dealing the second recent blow to the local biotechnology sector from a large drug developer.
Tue Sep 02, 2014
Denmark company buys NH biotech plant
A Denmark company has purchased a biotech plant in West Lebanon that was closing down.
Baxter Will Remain Diversified and With Competitive Advantages
In this article, let's take a look at Baxter International Inc. , a $40.61 billion market cap company, which is a global medical products and services company that provides critical therapies for people with life-threatening conditions.